Donepezil: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CONITEC (Brazil), HIRA (South Korea) and PHARMAC (New Zealand) recommended or restricted donepezil, while HAS (France) did not recommend it.
The file has been open for more than a decade: 18.8 years separate the first record, 19 Jul 2006 at HAS (France), from the most recent, 15 May 2025 at CONITEC (Brazil).
CIPM (Spain) changed its position: not recommended on 3 Mar 2021, recommended by 20 Sep 2023, after a resubmission.
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — PBAC (Australia), SMC (Scotland) and AWMSG (Wales) among them — hold no record for donepezil at all.
The file is active: 3 of 12 records date from 2023 or later.
Against its own class, donepezil is an outlier: 62% of its decisive outcomes were positive, where molecules sharing ATC class N06D average 38%.
HAS (France) was first to assess donepezil, on 19 Jul 2006; CONITEC (Brazil) did not open a file until 15 May 2025 — an unusually long tail of 18.8 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 9 years in total.
Restriction is doing real work here: 2 of 8 decisive outcomes narrowed donepezil to a subgroup rather than accepting or refusing it outright, at HIRA (South Korea) and PHARMAC (New Zealand).
2 of the 5 agencies here assessed donepezil more than once, HAS (France) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed donepezil.
The full ledger for donepezil reads 4 other, 3 recommended, 3 not recommended and 2 restricted.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CONITEC (Brazil) | 15 May 2025 | Tratamento de pacientes com doença de Alzheimer grave. | incorporated into SUS | source |
| HIRA (South Korea) | 12 May 2022 | 아이큐어 (주) 알츠하이머형 치매증상의 치료 | reimbursable only at the evaluated price | source |
| CIPM (Spain) | 30 Sep 2021 | Indicación terapéutica autorizada: Dezipar está indicado como terapia de sustitución en el tratamiento de la enfermedad … | not financed by the SNS (financed 2023-09) | source |
| HAS (France) | 19 Oct 2011 | Re-assessment of SMR and ASMR | ASMR V | source |
| PHARMAC (New Zealand) | 23 Jul 2008 | Alzheimer's disease (Dementia) | PTAC advice: Low · decision reached | source |
7 further decisions for donepezil, across 2 agencies, are not shown here. They link to 3 further source documents.
Related molecules
- memantine — same ATC class N06D — Psychoanaleptics
- lecanemab — same ATC class N06D — Psychoanaleptics
- donanemab — same ATC class N06D — Psychoanaleptics
- galantamine — same ATC class N06D — Psychoanaleptics
- rivastigmine — same ATC class N06D — Psychoanaleptics
- trastuzumab — also decided by CONITEC in 2025Q2
Coverage: 12 decisions for donepezil from 5 agencies, 2006 to 2025. Data to 7 Sep 2026. ATC class N06D — Psychoanaleptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.